132 studies on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that retatrutide, a novel triple agonist, is highly effective in reducing liver fat and achieving MASLD resolution in a substantial proportion of patients. The remarkable rates …
This review underscores the transformative potential of GIP receptor-based therapies as a powerful new class of drugs for obesity management. The impressive weight loss and metabolic improvements observed suggest thes…
This review significantly advances our understanding of the multifaceted nature of obesity, providing a robust framework for developing more effective and personalized treatments. The detailed exploration of molecular…
This research highlights the potent renoprotective capabilities of multi-agonist incretin therapies, particularly Retatrutide, in managing Diabetic Kidney Disease. The superior efficacy of Retatrutide, which targets G…
This comprehensive comparison provides crucial evidence for clinicians and patients, guiding treatment decisions for obesity and overweight. The identification of most effective agents can lead to more personalized an…
This comprehensive meta-analysis solidifies retatrutide's position as a highly effective treatment for obesity and related metabolic disorders, offering a robust evidence base for its broad therapeutic potential. The …
This review is crucial for clinicians and researchers, underscoring the need for a paradigm shift in Type 2 Diabetes (T2D) management from a purely pharmacological approach to a holistic, integrated model. It emphasiz…
This systematic review provides compelling evidence that incretin therapies, especially GLP-1 receptor agonists, are not merely glucose-lowering agents but also offer significant cardiovascular protection for individu…
Preserving fat-free mass during weight loss is paramount for maintaining metabolic health, physical function, and reducing frailty, especially in older adults. This review underscores the urgent need for anti-obesity …
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This review underscores a transformative era in obesity management, moving beyond modest weight loss to therapies offering substantial and sustained reductions. The comprehensive overview provided by the authors is cr…
This comprehensive systematic review provides robust evidence that GLP-1 receptor agonists are highly effective and generally safe pharmacological interventions for significant weight loss in adults without diabetes. …
This comprehensive meta-analysis provides robust evidence supporting the superior efficacy and acceptable safety profile of retatrutide as a potent treatment for obesity. The substantial weight loss achieved, averagin…
This comprehensive quantitative comparison provides invaluable evidence for clinicians and patients, offering clear guidance on the expected weight loss from different GLP-1 RAs. The findings underscore the varying po…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This study provides crucial, evidence-based insights into the comparative efficacy and safety of available GLP-1 RAs, offering a clear hierarchy of their weight reduction capabilities. The findings highlight that newe…
This review underscores the transformative potential of GLP-1RAs in addressing the global obesity epidemic and its related health burdens. The significant and sustained weight loss observed with these agents, coupled …
Understanding these sex-specific differences is crucial for advancing personalized medicine approaches in obesity and type 2 diabetes management. This finding suggests that biological sex may be an important factor in…
This review underscores the significant potential of repurposing GLP-1 RAs as a novel therapeutic strategy for a range of psychiatric illnesses, offering a promising avenue to address current treatment gaps and mitiga…
This systematic review provides compelling evidence for the superior efficacy of semaglutide among current pharmacological options for obesity management. The substantial weight loss achieved with semaglutide, a GLP-1…
This comprehensive meta-analysis provides strong evidence supporting retatrutide's exceptional efficacy and acceptable safety profile, positioning it as a highly promising therapeutic option for individuals with obesi…
This research is profoundly significant as it uncovers a direct cardiac effect of retatrutide, distinct from its well-documented metabolic actions. Understanding these direct myocardial influences is paramount for dev…
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This comprehensive meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in treating both MASLD and MASH, addressing a critical unmet medical need. The significant rates of MASH …
Antiobesity medications offer a dual therapeutic strategy for managing both obesity and the often-coexisting MASLD, a condition with limited approved treatments. This review highlights their potential to become a corn…
Retatrutide's unprecedented efficacy in achieving substantial weight loss and improving metabolic markers positions it as a potential paradigm shift in obesity pharmacotherapy. Its unique mechanism as a triple agonist…
This review underscores the transformative potential of incretin-based therapies in combating the complex challenges of obesity and its comorbidities. By providing a comprehensive overview of their efficacy and safety…
These findings are highly significant, demonstrating retatrutide's potential as a comprehensive treatment for type 2 diabetes that not only manages blood sugar but also profoundly improves body composition by reducing…
This study provides crucial insights into the direct cardiac actions of retatrutide, suggesting it may have a beneficial or at least neutral impact on heart muscle function. Understanding these direct effects is vital…
This study provides compelling evidence that Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, offers direct and indirect benefits for kidney health in individuals with Type 2 Diabetes …
This comprehensive NMA provides crucial evidence supporting the superior efficacy of multi-receptor agonists like retatrutide and tirzepatide over single GLP-1 RAs for significant weight loss in adults with overweight…
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating…
This research provides crucial insights into the mechanism of action of retatrutide beyond its known effects on glucose and weight regulation, highlighting its potential role in lipid metabolism. Understanding that re…
This comprehensive review solidifies retatrutide's potential as a highly effective treatment for obesity, offering superior weight loss compared to existing therapies by targeting GLP-1, GIP, and glucagon receptors. T…
This review underscores the rapid evolution of pharmacotherapy for obesity, moving beyond traditional approaches to highly effective hormonal analogues that mimic natural satiety signals. The findings suggest a future…
This review highlights the significant potential of triple agonists to offer a more potent and comprehensive therapeutic strategy for obesity and its associated metabolic complications. The synergistic activation of G…
These findings suggest that Peptide-X could represent a powerful new therapeutic strategy for obesity and its associated metabolic complications. The significant and sustained weight loss, coupled with improvements in…
This study provides compelling, high-level evidence that incretin-based therapies offer significant cardiovascular benefits beyond glycemic control and weight management, specifically by consistently lowering blood pr…
This study highlights the potential of retatrutide to not only manage blood glucose but also to directly address the underlying appetite dysregulation in type 2 diabetes and obesity. By improving appetite control and …